ABMC Promotes Todd Bailey to Vice President of Sales and Marketing.Business Editors KINDERHOOK, N.Y.--(BUSINESS WIRE)--Sept. 29, 2003 American Bio Medica medica (māˑ·dē·k Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ABMC ABMC American Battle Monuments Commission ABMC Alexian Brothers Medical Center (Illinois) ABMC Aviation Battle Management Concept ABMC Arrowbear Music Camp (California) ) announced today that Todd Bailey has been named Vice President of Sales and Marketing. In his new role, Bailey will be responsible for driving and managing all aspects of the Company's sales and distribution objectives across the U.S. and internationally. In addition to cultivating sales through new and existing sales channels, Bailey will spearhead vertical growth strategies, introduce new product lines and arm the sales force with high-impact marketing programs. He will also continue to build strong relationships with the Company's existing and future key national accounts. Bailey joined ABMC in April 2001 as a Director of Business Development and most recently was ABMC's Director of National Accounts. Prior to joining ABMC, Bailey was Substance Abuse Account Manager for Roche Diagnostics Roche Diagnostics Division is a subsidiary of Hoffmann-La Roche which manufactures equipment and reagents for research and medical diagnostic applications. Internally, it is organized into six major business areas: Roche Applied Science, Roche Centralized Diagnostics, Roche Corporation where he was responsible for territory sales of point-of-collection tests for drugs of abuse, to Fortune 500 manufacturers and state agencies. ABMC interim Chief Executive Officer Donal Carroll stated, "I am delighted to announce Todd's promotion to Vice President, Sales and Marketing. Since joining ABMC, Todd has proven his outstanding sales capabilities and has played a key role in the growth of ABMC. His extensive industry experience and his proven track record for consistently increasing sales make him the perfect person to help us achieve our future sales growth targets." Carroll added, "His promotion to vice president reflects not only ABMC's respect for his past achievements, but our confidence in his ability to positively impact ABMC's future market position." About American Bio Medica Corporation American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay Immunoassay An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. diagnostic test kits, including some of the world's most effective point-of-collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen(R), Rapid One(R), Rapid Tec(R) and Rapid Tec Cup(TM) products test for the presence or absence of drugs of abuse in urine urine, clear, amber-colored fluid formed by the kidneys that carries metabolic wastes out of the body (see urinary system). As the blood circulates it collects excretory products from the tissues and these substances are separated from the blood by the kidneys and , while OralStat(R) tests for the presence or absence of drugs of abuse in saliva saliva Thick, colourless fluid constantly present in the mouth, composed of water, mucus, proteins, mineral salts, and amylase, an enzyme that breaks down starches. One to two litres are produced daily by the salivary glands. . ABMC has been named among the 2002 Deloitte & Touche Technology Fast 500, a listing of the fastest-growing technology companies in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. . This release may contain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled en·ti·tle tr.v. en·ti·tled, en·ti·tling, en·ti·tles 1. To give a name or title to. 2. To furnish with a right or claim to something: "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2002, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion